A Randomized, Open-Label, Parallel-Cohort, Single-dose and Multiple-dose Phase I Study of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Prusogliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 02 Apr 2022 Status changed from not yet recruiting to completed.
- 08 Dec 2021 New trial record